Is Methocarbamol or Cyclobenzaprine Better?

No high-quality head-to-head trial has ever shown one of these drugs to be clearly superior to the other. A systematic review of skeletal muscle relaxants concluded there is insufficient evidence to determine the relative efficacy or safety of cyclobenzaprine, methocarbamol, and several other common muscle relaxants.¹ That leaves you and your prescriber choosing between them based on side-effect profiles, drug interactions, how sedating each one is, and what you need to be doing while you take it. Those differences, while not dramatic, are real and worth understanding.

Why There Is No Simple Answer

Cyclobenzaprine is far and away the more studied drug. It has been the subject of dozens of randomized trials, mostly for acute musculoskeletal pain. Methocarbamol, by contrast, has a much thinner evidence base. The same systematic review that evaluated both drugs found very limited or inconsistent data on methocarbamol’s effectiveness compared to placebo, while cyclobenzaprine at least had more consistent short-term trial data showing modest benefit over placebo for muscle spasm.¹ That does not mean methocarbamol is less effective. It means researchers have not studied it as thoroughly. The absence of evidence is not evidence of absence, but it does mean you should be skeptical of anyone who claims methocarbamol is “just as good” or “better” based on clinical data alone.

What clinicians rely on instead is decades of prescribing experience, patient preference, and known pharmacology. Both drugs are approved for short-term relief of muscle spasm associated with acute musculoskeletal conditions, and both are meant to be used alongside rest, physical therapy, and anti-inflammatory drugs rather than as standalone treatments. In practice, the choice often comes down to how each one makes you feel and what else you are taking.

How They Work Differently

Both methocarbamol and cyclobenzaprine are centrally acting muscle relaxants, meaning they work in the brain and spinal cord rather than directly on the muscles themselves. But their mechanisms diverge from there in ways that matter for side effects and drug interactions.

Methocarbamol’s exact mechanism is not fully understood. It appears to depress nerve transmission in the spinal cord and possibly in subcortical brain areas, producing a general sedative effect that reduces muscle spasm indirectly. It does not have strong affinity for the same neurotransmitter receptors that get cyclobenzaprine into trouble.

Cyclobenzaprine, on the other hand, has a very specific chemical identity: it is structurally almost identical to amitriptyline, a tricyclic antidepressant. The two drugs share an identical cyclic structure.² That structural kinship means cyclobenzaprine binds to a wide array of receptors: serotonin, histamine, acetylcholine (muscarinic), and alpha-adrenergic receptors. This broad receptor activity explains why cyclobenzaprine is effective at reducing muscle spasm but also why it causes a wider range of side effects than methocarbamol. The histamine-receptor blockade is a major reason cyclobenzaprine makes people so drowsy. The muscarinic blockade is why it causes dry mouth, constipation, and urinary retention. And the serotonin activity is why it carries a risk that methocarbamol essentially does not.

Sedation and Side Effects

Both drugs cause drowsiness. That is largely the point: part of how centrally acting muscle relaxants reduce spasm is by dialing down nervous system activity, and sedation is a predictable companion to that effect. But the character and intensity of that sedation differ.

Cyclobenzaprine tends to produce heavier sedation, especially at the traditional dose of 10 mg three times daily. Many prescribers now start at 5 mg to reduce this. Because cyclobenzaprine hits so many receptor types, its side-effect profile reads like a tricyclic antidepressant’s: drowsiness, dry mouth, dizziness, blurred vision, and constipation are all common. Some patients describe a “foggy” or “hung-over” feeling that persists well into the next day.

Methocarbamol also causes drowsiness and dizziness, but patients generally report these effects as milder and shorter-lived. It does not have the anticholinergic burden that cyclobenzaprine carries, so the dry mouth, constipation, and urinary issues are less prominent. For people who find cyclobenzaprine’s side effects intolerable, methocarbamol is a common next step precisely because it tends to be more manageable. That said, “milder side effects” is a population-level generalization; individual responses vary enough that some people tolerate cyclobenzaprine just fine and find methocarbamol unhelpful.

Driving and Next-Day Impairment

If you need to work, drive, or stay alert during the day, the sedation question is not academic. A driving-simulation study compared cyclobenzaprine to placebo and found that subjects who received cyclobenzaprine showed significant impairment in their ability to maintain lane position, along with deficits on most secondary measures of driving ability.³ The particularly striking part: despite performing measurably worse behind the wheel, only about 10% of subjects on day one and about 3% on day two reported feeling unsafe to drive.³ In other words, the drug impaired performance without people realizing it.

Methocarbamol has not been studied as rigorously in driving simulation trials, so a direct comparison on this specific measure does not exist. Clinically, though, methocarbamol is generally regarded as less impairing, which is part of why some clinicians favor it for patients who cannot afford to lose a workday to sedation. Still, any centrally acting muscle relaxant can impair your reaction time, and the standard label advice for both drugs is to avoid driving or operating machinery until you know how the medication affects you.

The Serotonin Syndrome Risk

This is where the two drugs diverge sharply in terms of safety, and it is the single most important pharmacological distinction between them for many patients. Cyclobenzaprine blocks serotonin and norepinephrine transporters and binds to multiple serotonin receptors.⁴ That means combining it with other drugs that increase serotonin levels can push you into serotonin syndrome, a potentially dangerous condition characterized by agitation, rapid heart rate, high blood pressure, fever, muscle rigidity, and in severe cases, seizures or organ failure.

Case reports have documented severe serotonin syndrome in patients who were given cyclobenzaprine while already taking another serotonin-enhancing drug. In two reported cases, symptoms of autonomic instability and severe agitation started within hours of starting cyclobenzaprine in patients who were on either a monoamine oxidase inhibitor or an SNRI antidepressant; symptoms fully resolved within three days of stopping the serotonergic drugs.⁵ The conclusion from those case reports was that cyclobenzaprine should be used with extreme caution in anyone already on serotonin-enhancing medications.⁵

This matters because a huge portion of the adult population takes some form of serotonin-active medication. SSRIs and SNRIs are among the most commonly prescribed drugs in the United States. Triptans for migraine, tramadol for pain, and certain anti-nausea medications also increase serotonin activity. If you take any of these, cyclobenzaprine introduces a real interaction risk. Methocarbamol does not have this serotonin pharmacology and does not carry this same concern. For patients already on antidepressants, methocarbamol is often the safer default, and many clinicians consider this a strong tiebreaker.

Older Adults and Anticholinergic Load

Cyclobenzaprine appears on the American Geriatrics Society’s Beers Criteria list of medications that are potentially inappropriate for adults 65 and older. The reasons trace back to its tricyclic structure: the anticholinergic effects (confusion, urinary retention, constipation, dry mouth) are more burdensome and more dangerous in older patients, who may already be taking other medications with anticholinergic properties. Stacking anticholinergic drugs increases the total “anticholinergic load” on the brain, and in older adults this has been linked to increased fall risk, cognitive impairment, and delirium.

Methocarbamol is not free of concerns in this population, since any sedating drug raises fall risk. But it does not carry the same anticholinergic baggage, which is why geriatricians tend to prefer it when a muscle relaxant is truly needed. In general, prescribers try to avoid both drugs in older adults when possible and opt for non-pharmacological approaches, but when a muscle relaxant is warranted, methocarbamol usually wins by default in this age group.

What About Acute Low Back Pain

Acute low back pain is one of the most common reasons either drug gets prescribed. Here, it is worth looking at what the evidence actually shows for cyclobenzaprine added to a standard anti-inflammatory. A randomized trial published in JAMA enrolled emergency department patients with acute, nontraumatic, non-radiating low back pain and compared naproxen alone to naproxen plus cyclobenzaprine (or naproxen plus oxycodone/acetaminophen). Adding cyclobenzaprine to naproxen did not improve functional outcomes or pain at one-week follow-up.⁶ The study’s conclusion was blunt: these findings do not support use of these additional medications in that setting.⁶

That trial did not include a methocarbamol arm, so we cannot say methocarbamol would have performed differently. But it does raise an uncomfortable question: for the most common indication these drugs are prescribed for, do muscle relaxants add meaningful benefit at all when a good anti-inflammatory is already on board? The evidence for cyclobenzaprine in that specific scenario says no. This is worth keeping in mind if your doctor suggests adding a muscle relaxant to ibuprofen or naproxen for a back strain. The additional sedation may not come with additional pain relief.

Long-Term Use and Off-Label Applications

Neither drug is meant for long-term use. Prescribing guidelines generally recommend muscle relaxants for no more than two to three weeks for acute musculoskeletal conditions. The rationale is that acute muscle spasm should resolve within that window, and the sedation and other side effects become harder to justify as the condition improves.

That said, cyclobenzaprine has been studied off-label for fibromyalgia, where chronic widespread pain and sleep disturbance are hallmarks. A systematic review of muscle relaxants for chronic pain found that cyclobenzaprine was associated with improvement in sleep disturbance in fibromyalgia patients, but showed no difference from placebo in other outcomes like pain or physical function.⁷ So if your main complaint is that pain keeps you from sleeping, low-dose cyclobenzaprine might help with that specific piece. But if you are hoping it will reduce your overall pain levels in a chronic condition, the evidence is not encouraging.

Methocarbamol has not been studied much for chronic pain or fibromyalgia, so there is not a comparable body of evidence to evaluate. In practice, some patients do take it longer-term for recurrent muscle spasm conditions, but this is done without strong trial support and on a case-by-case basis.

Cost and Availability

Both methocarbamol and cyclobenzaprine are available as generics and are relatively inexpensive. Methocarbamol is also available over the counter in Canada and some other countries under the brand name Robaxin, though in the United States it requires a prescription. Cyclobenzaprine is prescription-only everywhere. Neither drug is a controlled substance in the US, which means no special prescribing restrictions and generally easier refills than something like carisoprodol, another muscle relaxant that is a Schedule IV controlled substance due to its abuse potential.

Insurance coverage is rarely a deciding factor between the two since both generics are cheap and widely covered. If you are paying out of pocket, methocarbamol and cyclobenzaprine typically cost in the same ballpark for a short course. The practical accessibility of the two drugs is essentially equal.

When One Might Be Preferred Over the Other

Given the lack of head-to-head efficacy data, the choice usually comes down to the patient sitting in front of the prescriber and what their situation looks like. Some patterns emerge from the pharmacology and available evidence:

On an antidepressant: Methocarbamol avoids the serotonin syndrome risk that comes with cyclobenzaprine. This applies to SSRIs, SNRIs, MAOIs, and other serotonin-active drugs.
Age 65 or older: Methocarbamol is generally preferred because cyclobenzaprine’s anticholinergic effects make it potentially inappropriate in this group.
Need to stay functional during the day: Methocarbamol is usually less sedating, though both drugs can impair you. Taking either one only at bedtime is a common strategy.
Sleep disruption is the main problem: Cyclobenzaprine’s stronger sedation and its modest evidence for improving sleep in fibromyalgia might make it the better pick, used at a low dose before bed.
Prominent muscle spasm with no significant drug interactions: Cyclobenzaprine has the stronger evidence base for short-term spasm relief, and some clinicians consider it slightly more effective for this purpose based on available trials, though the evidence for superiority over methocarbamol specifically is not there.

Neither drug is a magic bullet. Both work best as part of a broader approach that includes anti-inflammatory medication, gentle activity, and time. For many episodes of acute musculoskeletal pain, the muscle relaxant is the least important part of the treatment plan, and the JAMA trial on low back pain suggests it may not add benefit at all when paired with an effective anti-inflammatory.⁶

Alcohol and Abuse Potential

Both methocarbamol and cyclobenzaprine amplify the effects of alcohol and other central nervous system depressants. Combining either one with alcohol increases sedation, impairs coordination, and raises the risk of respiratory depression in extreme cases. This is a standard warning for all centrally acting muscle relaxants, but it bears emphasis because plenty of people pop a muscle relaxant for a back strain and then have a beer with dinner without thinking twice.

Neither drug is considered to have high abuse potential, which is why neither is scheduled as a controlled substance in the US. Carisoprodol (Soma), by comparison, was placed in Schedule IV specifically because of widespread recreational misuse. Cyclobenzaprine does show up in some reports of misuse, usually in combination with other drugs, but it does not produce the euphoria or “high” that makes certain other muscle relaxants targets for abuse. Methocarbamol has even less abuse-related concern. If a prescriber is worried about a patient’s substance use history, methocarbamol is the more conservative choice for this reason as well.